{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:57:22Z","timestamp":1781139442243,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ijmmb.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:46:08Z","timestamp":1630482368000},"page":"101-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["In vitro activity of ceftaroline and other antimicrobial agents against Gram positive bacterial isolates: Descriptive study from a university hospital"],"prefix":"10.1016","volume":"40","author":[{"given":"Tasneem","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-7717","authenticated-orcid":false,"given":"Chinmoy","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangram Singh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijmmb.2021.08.003_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib2","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/JCM.00177-15","article-title":"Implementation of matrix-assisted laser desorption ionization-time of flight mass spectrometry in routine clinical laboratories improves identification of coagulase-negative staphylococci and reveals the pathogenic role of Staphylococcus lugdunensis","volume":"53","author":"Argemi","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/CMR.00109-13","article-title":"Coagulase-negative staphylococci","volume":"27","author":"Becker","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/JCM.01024-08","article-title":"Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community","volume":"47","author":"Bocher","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"issue":"Suppl 4","key":"10.1016\/j.ijmmb.2021.08.003_bib5","first-page":"iv9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib6","first-page":"a2466","article-title":"Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA)","volume":"3","author":"Duplessis","year":"2011","journal-title":"Clin Med Rev Therapeut"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib7","series-title":"Performance Standards for antimicrobial susceptibility testing. 30thed","author":"CLSI","year":"2020"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib8","article-title":"Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence and susceptibility pattern","volume":"137","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib9","first-page":"49","article-title":"Prevalence of methicillin resistant Staphylococcus aureus in a tertiary referral hospital in Eastern Uttar Pradesh","volume":"21","author":"Anupurba","year":"2003","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib10","series-title":"Annual report antimicrobial resistance surveillance and research Network January 2019 to December 2019 ,AMR surveillance Network","first-page":"85","year":"2019"},{"issue":"10","key":"10.1016\/j.ijmmb.2021.08.003_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1995-7645(12)60155-2","article-title":"Linezolid resistant Staphylococcus haemolyticus: first case report from India","volume":"5","author":"Gupta","year":"2012","journal-title":"Asian Pacif J Trop Med"},{"issue":"717","key":"10.1016\/j.ijmmb.2021.08.003_bib12","first-page":"1","article-title":"Linezolid resistant coagulase negative staphylococci (LRCoNS) with novel mutations causing blood stream infections (BSI) in India","volume":"19","author":"Mittal","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.ijmmb.2021.08.003_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2174\/1871526519666190807152850","article-title":"Linezolid resistance in Staphylococcus haemolyticus - case series and review of literature","volume":"20","author":"Gupta","year":"2020","journal-title":"Infect Disord - Drug Targets"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4103\/ijmr.IJMR_283_18","article-title":"Linezolid-resistant Staphylococcus haemolyticus: emergence of G2447U & C2534U mutations at the domain V of 23S ribosomal RNA gene in a tertiary care hospital in India","volume":"149","author":"Kumari","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/17460913.4.1.25","article-title":"Ceftaroline: a cephalosporin with expanded Gram- positive activity","volume":"4","author":"Kanafani","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/AAC.01351-07","article-title":"Antimicrobial activities of ceftaroine and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus","volume":"52","author":"Sader","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib19","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib20","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial SusceptibilityTesting","year":"2009"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib21","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib22","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1128\/AAC.01242-06","article-title":"In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin- resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model","volume":"51","author":"Jacqueline","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib23","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/AAC.00636-09","article-title":"In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin- intermediate S.\u00a0aureus in a hollow fiber model","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/jac\/dki362","article-title":"Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests","volume":"56","author":"Jones","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib25","first-page":"73","article-title":"Coagulase-negative staphylococcal infections","volume":"23","author":"Rogers","year":"2009","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jiac.2015.02.012","article-title":"Optimizing antibiotic therapy of bacteremia and endocarditis due to Staphylococci and Enterococci: new insights and evidence from the liter-ature","volume":"21","author":"Falcone","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-013-0075-6","article-title":"Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia","volume":"73","author":"Frampton","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"10.1016\/j.ijmmb.2021.08.003_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13756-019-0523-5","article-title":"The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative Staphylococci bacteraemia in China","volume":"8","author":"Cui","year":"2019","journal-title":"Antimicrob Resist Infect Contr"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721041827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721041827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:19:58Z","timestamp":1759346398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085721041827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0255085721041827"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2021.08.003","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftaroline and other antimicrobial agents against Gram positive bacterial isolates: Descriptive study from a university hospital","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}